Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEACRAFT-2 in previously treated NRAS-mutant unresectable or metastatic cutaneous melanoma
NL-OMON60275Phase 3Completed
- Sponsor
- Erasca
- Start
- Oct 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of naporafenib, trametinib, dacarbazine and temozolomide in cutaneous melanoma (CM) (5 arms), sponsored by Erasca. Started Oct 2024; status: completed.
02
Drugs
naporafenibtrametinibdacarbazinetemozolomide
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON60275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60275.